SCHEMBL14723247

SCHEMBL14723247

CN(C(=O)O)c1cc2c(cc1F)ncn2C1CCCCO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 2/20 0.37
GAA P10253 1/20 0.37
CYP4F2 P78329 2/20 0.37
CYP4A11 Q02928 2/20 0.37
YTHDC1 Q96MU7 1/20 0.35
LMNA P02545 1/20 0.34
ESR1 P03372 1/20 0.34
MAPT P10636 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
TP53 P04637 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14723427 0.83 HTR2C (0.37) IDO1CYP2C19HSD17B10GAACYP4F2
SCHEMBL15208541 0.81 GAA (0.46) CYP2C19HSD17B10GAACYP4F2CYP4A11
SCHEMBL15209975 0.78 YTHDC1 (0.44) CYP2C19HSD17B10GAACYP4F2CYP4A11
SCHEMBL14723072 0.78 CYP2C19 (0.42) CYP2C19HSD17B10GAACYP4F2CYP4A11
SCHEMBL14723035 0.77 YTHDC1 (0.43) CYP2C19HSD17B10GAACYP4F2CYP4A11
SCHEMBL14723246 0.77 CYP4F2 (0.38) IDO1CYP2C19HSD17B10GAACYP4F2
SCHEMBL15216611 0.76 CYP2C19 (0.41) IDO1CYP2C19HSD17B10GAACYP4F2
SCHEMBL14722763 0.75 CYP2C19 (0.39) IDO1CYP2C19HSD17B10CYP4F2CYP4A11
SCHEMBL14722928 0.74 CYP2C19 (0.43) CYP2C19HSD17B10GAACYP4F2CYP4A11
SCHEMBL14722645 0.74 CYP2C19 (0.39) CYP2C19HSD17B10GAACYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2748159-A1 SERINE/THREONINE PAK1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-07-02 EP disclosed
US-8637537-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2014-01-28 US disclosed
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-08-29 US disclosed
WO-2013026914-A1 SERINE/THREONINE PAK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 IDO1 4606/4885CYP2C19 4851/4885HSD17B10 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.